Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 11 results.
User Information
Export Records
  1. 1.   Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
  2. Mehrotra, Shailly; Gopalakrishnan, Mathangi; Gobburu, Jogarao; Ji, Jay; Greer, Jacqueline M.; Piekarz, Richard; Karp, Judith E.; Pratz, Keith W.; Rudek, Michelle A.
  3. CLINICAL CANCER RESEARCH. 2017, NOV 1; 23(21): 6421-6429.
  1. 2.   ASPS-1, A Novel Cell Line Manifesting Key Features of Alveolar Soft Part Sarcoma
  2. Kenney, S.; Vistica, D. T.; Stockwin, L. H.; Burkett, S.; Hollingshead, M. G.; Borgel, S. D.; Butcher, D. O.; Schrump, D. S.; Shoemaker, R. H.
  3. Journal of Pediatric Hematology Oncology. 2011, Jul; 33(5): 360-368.
  1. 3.   Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
  2. Pfister, T. D.; Reinhold, W. C.; Agama, K.; Gupta, S.; Khin, S. A.; Kinders, R. J.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.; Pommier, Y.
  3. Molecular Cancer Therapeutics. 2009 8(7): 1878-1884.
  1. 4.   Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy
  2. Vistica, D. T.; Hollingshead, M.; Borgel, S. D.; Kenney, S.; Stockwin, L. H.; Raffeld, M.; Schrump, D. S.; Burkett, S.; Stone, G.; Butcher, D. O.; Shoemaker, R. H.
  3. Journal of Pediatric Hematology Oncology. 2009 31(8): 561-570.
  1. 5.   Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles
  2. Nagarajan, M.; Morrell, A.; Ioanoviciu, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Hollingshead, M.; Pommier, Y.; Cushman, M.
  3. Journal of Medicinal Chemistry. 2006, Oct; 49(21): 6283-6289.
  1. 6.   Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors
  2. Nagarajan, M.; Morrell, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Pommier, Y.; Ragazzon, P. A.; Garbett, N. C.; Chaires, J. B.; Hollingshead, M.; Cushman, M.
  3. Journal of Medicinal Chemistry. 2006, Aug; 49(17): 5129-5140.
  1. 7.   Topotecan inhibits HIF-1 alpha, but not HIF-2 alpha, protein accumulation and tumor growth in human renal cancer cells
  2. Rapisarda, A.; Uranchimeg, B.; Hollingshead, M.; Borgel, S.; Carter, J.; Shoemaker, R. H.; Melillo, G.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9019S-9019S.
  1. 8.   Topotecan blocks hypoxia-inducible factor-1 alpha, and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells
  2. Beppu, Y.; Nakamura, K.; Linehan, W. M.; Rapisarda, A.; Thiele, C. J.
  3. Cancer Research. 2005, JUN 1; 65(11): 4775-4781.
  1. 9.   Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
  2. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004, OCT 1; 64(19): 6845-6848.
  1. 10.   Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
  2. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004 64(4): 1475-1482.
  1. 11.   Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells
  2. Honjo, Y.; Hrycyna, C. A.; Yan, Q. W.; Medina-Perez, W. Y.; Robey, R. W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S. E.
  3. Cancer Research. 2001 61(18): 6635-6639.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel